Idorsia Ltd. updated earnings guidance for the year 2023. Following the Sosei Deal, the cost reduction initiative, the portfolio review and the first nine months operations, the company is updating its full year 2023 financial guidance and expects a US GAAP operating loss of around CHF 670 million (previously CHF 735 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 CHF | +9.07% | -3.55% | -10.12% |
Apr. 26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
Apr. 11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.12% | 371M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- IDIA Stock
- News Idorsia Ltd
- Idorsia Ltd Updates Earnings Guidance for the Year 2023